Recent News

• 11.04.2026 - Ocugen Provides Business Update with Third Quarter 2026 Financial Results
• 10.29.2026 - Ocugen to Participate in Upcoming November Investor and Industry Conferences
• 10.22.2026 - Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
• 10.14.2026 - Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
• 10.06.2026 - Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
• 09.30.2026 - Ocugen to Participate in Upcoming Scientific Conferences
• 09.29.2026 - Ocugen to Participate in Upcoming October Investor and Industry Conferences
• 09.25.2026 - Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
• 09.01.2026 - Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
• 08.06.2026 - Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Recent Filings

• 11.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2026 - 8-K Current report
• 11.04.2026 - EX-99.1 EX-99.1
• 10.15.2026 - 8-K Current report
• 10.15.2026 - EX-99.1 EX-99.1
• 10.15.2026 - EX-99.1 EX-99.1
• 10.15.2026 - 8-K Current report
• 10.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.09.2026 - 144 Report of proposed sale of securities
• 10.06.2026 - 8-K Current report